Duloxetine Hydrochloride

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Depression

Conditions

Depression, Pain

Trial Timeline

Mar 1, 2002 → Jan 1, 2003

NCT ID

NCT00036335

About Duloxetine Hydrochloride

Duloxetine Hydrochloride is a phase 3 stage product being developed by Eli Lilly for Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT00036335. Target conditions include Depression, Pain.

What happened to similar drugs?

20 of 20 similar drugs in Depression were approved

Approved (20) Terminated (2) Active (0)

✅DuloxetineEli LillyApproved

✅duloxetineEli LillyApproved

✅DuloxetineEli LillyApproved

✅Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)Eli LillyApproved

✅DuloxetineEli LillyApproved

✅duloxetine + fluoxetine + citalopram + paroxetine + sertralineEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00071708	Pre-clinical	Completed	—	—	Major Depressive Disorder
NCT00960986	Approved	Completed	Aug 1, 2009	Apr 1, 2011	Major Depressive Disorder (MDD)
NCT00437125	Approved	Completed	Mar 1, 2007	Jul 1, 2009	Major Depressive Disorder
NCT00266643	Approved	Completed	Dec 1, 2005	Apr 1, 2007	Diabetic Neuropathy, Painful
NCT00583193	Phase 3	UNKNOWN	Dec 1, 2005	Jun 1, 2008	Posttraumatic Stress Disorders
NCT00191594	Phase 3	Completed	Mar 1, 2005	Aug 1, 2006	Major Depressive Disorder
NCT00191061	Approved	Completed	Oct 1, 2004	Jan 1, 2006	Depressive Disorder
NCT00479726	Approved	Completed	Aug 1, 2004	Jan 1, 2005	Major Depressive Disorder
NCT00036309	Phase 3	Completed	May 1, 2002	Jul 1, 2003	Depressive Disorder
NCT00036335	Phase 3	Completed	Mar 1, 2002	Jan 1, 2003	Depression

Competing Products

20 competing products in Depression

See all competitors

Product	Company	Stage	Hype Score
Olanzapine and Fluoxetine combination (OFC) + Fluoxetine	Eli Lilly	Phase 3	40
Duloxetine	Eli Lilly	Approved	35
FK949E	Astellas Pharma	Phase 3	40
Quetiapine	Astellas Pharma	Pre-clinical	26
duloxetine + escitalopram + placebo	Eli Lilly	Phase 3	40
duloxetine	Eli Lilly	Approved	43
Duloxetine	Eli Lilly	Approved	43
Duloxetine	Eli Lilly	Approved	43
Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)	Eli Lilly	Approved	43
Duloxetine + Placebo	Eli Lilly	Phase 3	40
Duloxetine	Eli Lilly	Approved	43
duloxetine + fluoxetine + citalopram + paroxetine + sertraline	Eli Lilly	Approved	43
Olanzapine + Placebo	Eli Lilly	Phase 3	40
Olanzapine + Fluoxetine + Placebo	Eli Lilly	Phase 3	32
duloxetine + duloxetine	Eli Lilly	Pre-clinical	26
olanzapine + ziprasidone	Eli Lilly	Approved	43
Olanzapine Fluoxetine Combination (OFC) + Placebo	Eli Lilly	Approved	43
Drug treatment with Cymbalta	Eli Lilly	Approved	39
Duloxetine	Eli Lilly	Approved	43
Duloxetine	Eli Lilly	Approved	39